Indications And Dose
Type 2 diabetes mellitus [in combination with metformin] ▶BY SUBCUTANEOUS INJECTION ▶Adult: (consult product literature)
PDF page 779
Loading InternPractice…
Drug reference
Type 2 diabetes mellitus [in combination with metformin] ▶BY SUBCUTANEOUS INJECTION ▶Adult: (consult product literature)
PDF page 779
Suliqua ® is available in two pen strengths, providing different dosing options. To avoid medication errors, the prescriber must ensure that the correct strength and number of dose steps is prescribed. The manufacturer of Suliqua ® has provided a healthcare professional guide and letter which includes important information on dosing.
PDF page 779
Scottish Medicines Consortium (SMC) decisions SMC No. SMC2235 The Scottish Medicines Consortium has advised (April 2020) that insulin glargine with lixisenatide (Suliqua ®) is accepted for restricted use within NHS Scotland for the treatment of adults with type 2 diabetes mellitus, in combination with metformin to improve glycaemic control in patients who are uncontrolled on basal insulin and for whom a GLP-1 receptor agonist is appropriate as an add- on intensification therapy to basal insulin analogues.
PDF page 779
→Appendix 1: insulins. lixisenatide
PDF page 779
There can be variation in the licensing of different medicines containing the same drug. Solution for injection CAUTIONARY AND ADVISORY LABELS 10 ▶Suliqua (Sanofi) A Lixisenatide 33 microgram per 1 ml, Insulin glargine 100 unit per 1 ml Suliqua 100units/ml / 33micrograms/ml solution for injection 3ml pre-filled SoloStar pens | 3 pre-filled disposable injection P £48.60 DT = £51.30 Lixisenatide 50 microgram per 1 ml, Insulin glargine 100 unit per 1 ml Suliqua 100units/ml / 50micrograms/ml solution for injection 3ml pre-filled SoloStar pens | 3 pre-filled disposable injection P £67.50 DT = £67.50 3.1a Diabetes, diagnosis and monitoring Diabetes mellitus, diagnostic and monitoring devices Endocrine system Urinalysis: urinary glucose Reagent strips are available for measuring for glucose in the urine. Tests for ketones by patients are rarely required unless they become unwell—see Blood Monitoring. Microalbuminuria can be detected with Micral-Test II ® but this should be followed by confirmation in the laboratory, since false positive results are common. Blood glucose monitoring Blood glucose monitoring using a meter gives a direct measure of the glucose concentration at the time of the test and can detect hypoglycaemia as well as hyperglycaemia. Patients should be properly trained in the use of blood glucose monitoring systems and to take appropriate action on the results obtained. Inadequate understanding of the normal fluctuations in blood glucose can lead to confusion and inappropriate action. Patients using multiple injection regimens should understand how to adjust their insulin dose according to their carbohydrate intake. With fixed-dose insulin regimens, the carbohydrate intake needs to be regulated, and should be distributed throughout the day to match the insulin regimen. Self-monitoring of blood-glucose concentration is appropriate for patients with type 2 diabetes: . who are treated with insulin; . who are treated with oral hypoglycaemic drugs e.g. sulfonylureas, to provide information on hypoglycaemia; . to monitor changes in blood-glucose concentration resulting from changes in lifestyle or medication, and during intercurrent illness; . to ensure safe blood-glucose concentration during activities, including driving. In the UK blood-glucose concentration is expressed in mmol/litre and Diabetes UK advises that these units should be used for self-monitoring of blood glucose. In other European countries units of mg/100 mL (or mg/dL) are commonly used. It is advisable to check that the meter is pre-set in the correct units. If the patient is unwell and diabetic ketoacidosis is suspected, blood ketones should be measured according to local guidelines. Patients and their carers should be trained in the use of blood ketone monitoring systems and to take appropriate action on the results obtained, including when to seek medical attention. Other drugs used for Diabetes, diagnosis and monitoring Glucose, p. 1102
PDF pages 779, 780
Manufacturer advises check pen label before each administration to avoid medication error. A patient guide should be provided.
PDF page 779
(consult product literature)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 779